Tratamiento con eritropoyetina en niños críticamente enfermos

  1. R. Chacón Aguilar
  2. M. Escorial Briso Montiano
  3. M. Sopetrán Rey García
  4. C. García Sanz
  5. M. Rupérez Lucas
  6. Jesús López Herce Cid
Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría ( AEP )

ISSN: 1695-4033 1696-4608

Year of publication: 2004

Volume: 61

Issue: 5

Pages: 398-402

Type: Article

More publications in: Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría ( AEP )


SCImago Journal Rank

  • Year 2004
  • SJR Journal Impact: 0.179
  • Best Quartile: Q3
  • Area: Pediatrics, Perinatology and Child Health Quartile: Q3 Rank in area: 147/241


Objective To analyze whether erythropoietin treatment increases hemoglobin and decreases transfusion requirements in critically ill children Patients and methods We performed an observational, prospective study of 23 critically ill children aged between 1 month and 6 years. Recombinant human eritropoietin (rHuEPO) was administered at a dosage of 150–750 U/kg/week over 3 days. Hemogram, reticulocyte, iron metabolism, serum ferritin and transferrin were measured before treatment started and weekly thereafter Results After erythropoietin treatment, hematocrit, hemoglobin and red blood cells progressively increased, with a maximal response in the sixth week. At the end of treatment, hemoglobin increased 1.68 g/dl, hematocrit by 5% and erythrocytes 600,000/ml/mm3. Transfusion requirements decreased from 59 transfusions at baseline to 12 in the first week of treatment and none from the sixth week. No treatment-related adverse effects were observed Conclusion Erythropoietin can be an effective treatment for anemia in some critically ill children, decreasing the number of transfusions and increasing hemoglobin